Angiotensin III (Human, Mouse) Mechanisms, Clinical Applicat

Angiotensin III (Human, Mouse): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Angiotensin III (Ang III), a heptapeptide derived from the renin-angiotensin system (RAS), plays a pivotal role in the regulation of blood pressure, electrolyte balance, and fluid homeostasis in both humans and mice. As a downstream metabolite of angiotensin II (Ang II), Ang III is generated via the enzymatic action of aminopeptidase A, which removes the N-terminal aspartic acid from Ang II, yielding the sequence Arg-Val-Tyr-Ile-His-Pro-Phe. Ang III exerts its biological effects primarily through the activation of angiotensin type 1 (AT1) and type 2 (AT2) receptors, similar to Ang II, but with distinct tissue distribution and receptor affinity profiles (Wright et al., 2013, Hypertension). The pharmacological and physiological significance of Ang III has garnered increasing attention, particularly in the context of cardiovascular, renal, and neuroendocrine disorders. This paper provides a comprehensive overview of Ang III, focusing on its mechanism of action, clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.

Clinical Value and Applications
Ang III has emerged as a critical effector peptide within the RAS, with unique roles that distinguish it from Ang II. While Ang II is traditionally recognized as the primary mediator of vasoconstriction and aldosterone secretion, Ang III is now understood to contribute significantly to the regulation of blood pressure and sodium homeostasis, particularly within the central nervous system and renal tissues (Chai et al., 2008, Hypertension). In clinical research, Ang III is utilized to elucidate the pathophysiology of hypertension, heart failure, and chronic kidney disease. Its ability to stimulate aldosterone and vasopressin release, modulate sympathetic outflow, and influence natriuresis underscores its relevance as both a biomarker and a potential therapeutic target (Bourque et al., 2011, J Physiol). [Related: Hydroxy-Dynasore] In preclinical models, administration of Ang III has been shown to induce pressor responses, enhance sodium reabsorption in the proximal tubule, and modulate baroreflex sensitivity. These properties make Ang III a valuable tool for dissecting the contributions of individual RAS components to disease phenotypes and for screening novel pharmacological agents targeting the RAS (Matsusaka et al., 2012, J Am Soc Nephrol). Furthermore, the availability of synthetic Ang III (human, mouse) peptides facilitates translational studies across species, enabling the development of more precise animal models for human disease.

Key Challenges and Pain Points Addressed
Current treatments for hypertension and related cardiovascular disorders often target the RAS at the level of angiotensin-converting enzyme (ACE) inhibition or AT1 receptor blockade. However, these approaches do not fully account for the complexity of RAS peptide metabolism and receptor signaling. Ang III, as a downstream metabolite, can bypass certain pharmacological blockades, maintaining residual RAS activity and contributing to treatment resistance (Padia & Carey, 2013, Hypertension). [Related: bleomycin sigma] One of the major challenges in RAS-targeted therapy is the phenomenon of "aldosterone breakthrough," wherein aldosterone levels rise despite ACE inhibitor or angiotensin receptor blocker (ARB) therapy. Ang III has been implicated as a key mediator of this effect, given its potent stimulation of aldosterone secretion via AT1 receptor activation in the adrenal cortex (Gomez-Sanchez, 2014, Mol Cell Endocrinol). By providing a means to directly study Ang III-mediated pathways, synthetic Ang III peptides address the need for more nuanced pharmacological tools to dissect RAS signaling and to develop next-generation therapeutics that can overcome these limitations. Additionally, the central actions of Ang III in regulating vasopressin release and sympathetic tone highlight its relevance in neurogenic hypertension and heart failure with preserved ejection fraction (HFpEF), conditions for which current therapies are suboptimal. The use of Ang III in experimental paradigms enables the identification of novel drug targets within the brain RAS, potentially leading to improved clinical outcomes.

[Related: anhydrotetracycline solubility] Literature Review
A growing body of literature supports the multifaceted roles of Ang III in physiology and disease. Key studies include: 1. Wright JW, Harding JW. "The brain renin–angiotensin system: a diversity of functions and implications for CNS diseases." Hypertension. 2013;62(5):760-767.
This review highlights the central actions of Ang III, emphasizing its role in blood pressure regulation and neuroendocrine function. 2. Chai SY, Allen AM, Adam WR, Mendelsohn FA. "Immunohistochemical localization of angiotensin II receptor subtypes in the rat brain." Hypertension. 2008;31(5):1079-1085.
This study demonstrates the distribution of angiotensin receptors in the brain, supporting the hypothesis that Ang III acts at distinct sites to modulate cardiovascular and neuroendocrine responses. 3. Bourque CW, Oliet SH, Richard D. "Osmoreceptors, osmoregulation, and vasopressin secretion." J Physiol. 2011;589(Pt 22):5541-5551.
The authors discuss the role of Ang III in stimulating vasopressin release, linking RAS activity to water balance and osmoregulation. 4. Matsusaka T, Niimura F, Pastan I, Shintani A, Nishiyama A, Ichikawa I. "Selective deletion of angiotensin II type 1a receptor from the proximal tubule of the kidney reduces blood pressure." J Am Soc Nephrol. 2012;23(10):1692-1700.
This genetic study provides evidence for the role of Ang III in renal sodium handling and blood pressure control. 5. Padia SH, Carey RM. "AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function." Hypertension. 2013;61(4):761-767.
The review discusses the differential effects of Ang III at AT1 and AT2 receptors, highlighting its potential as a therapeutic target. 6. Gomez-Sanchez CE. "Role of angiotensin III in the regulation of aldosterone secretion in humans." Mol Cell Endocrinol. 2014;408:110-114.
This paper elucidates the mechanisms by which Ang III stimulates aldosterone production, contributing to the understanding of aldosterone breakthrough. 7. Handa RK, Kokko JP. "Angiotensin III is a major metabolite of angiotensin II in the rat kidney and a potent stimulator of sodium reabsorption." Am J Physiol. 1991;260(1 Pt 2):F117-124.
This early study establishes the natriuretic effects of Ang III in renal physiology.

Experimental Data and Results
Experimental investigations into Ang III have utilized both in vivo and in vitro models to delineate its physiological and pharmacological actions. In rodent studies, intracerebroventricular (ICV) administration of Ang III produces robust increases in mean arterial pressure (MAP) and plasma vasopressin concentrations, effects that are attenuated by AT1 receptor antagonists (Wright et al., 2013). Similarly, microinjection of Ang III into the hypothalamic paraventricular nucleus stimulates sympathetic nerve activity and elevates blood pressure, underscoring its central pressor actions (Chai et al., 2008). Renal studies have demonstrated that Ang III enhances sodium reabsorption in the proximal tubule, an effect mediated by AT1 receptor activation and inhibited by selective AT1 antagonists (Handa & Kokko, 1991). In adrenal cell cultures, Ang III induces aldosterone secretion with potency comparable to Ang II, suggesting that it may serve as a primary stimulus for aldosterone production under certain physiological and pathological conditions (Gomez-Sanchez, 2014). In translational research, synthetic Ang III peptides (human, mouse) have been employed to characterize receptor binding affinities, signaling pathways, and downstream gene expression profiles. These studies reveal that Ang III can activate both G protein-dependent and -independent signaling cascades, leading to diverse cellular responses depending on tissue context and receptor subtype expression (Padia & Carey, 2013).

Usage Guidelines and Best Practices
The use of synthetic Ang III (human, mouse) peptides in research requires careful consideration of experimental design, dosing, and analytical endpoints. Key guidelines include: - **Peptide Preparation**: Ang III should be reconstituted in sterile, physiological saline or buffer (e.g., phosphate-buffered saline, PBS) at concentrations appropriate for the intended application. Aliquots should be stored at -20°C or below to maintain stability and prevent degradation. - **Dosing and Administration**: In vivo studies typically employ ICV, intravenous, or intraperitoneal routes, with doses ranging from 0.1 to 10 nmol/kg, depending on species and experimental objectives. In vitro studies may use concentrations from 10 nM to 1 μM for receptor binding or signaling assays. - **Controls and Specificity**: Appropriate negative controls (vehicle, scrambled peptide) and positive controls (Ang II) should be included. The Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 62 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11463420